Title
Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer
Publication Date
2014
Journal Title
Kidney Int
Abstract
Treatment of anemia remains an important component in the care of patients with nondialysis chronic kidney disease (CKD) and end-stage renal disease (ESRD). Erythropoietin-stimulating agents (ESAs) remains a key anemia treatment strategy in this patient population. However, anemia management in this group can become more complicated by prior or current history of malignancy. There has been a great deal of work both scientifically and in clinical trials in oncology that have revealed certain concerns and risks of ESA use in patients with cancer. In this review, we will bring together knowledge from nephrology and oncology literature to help nephrologists understand the implications for ESA treatment when CKD/ESRD is complicated by cancer. We also suggest an approach to the management of anemia in this patient group with active or previous malignancy.
Volume Number
86
Issue Number
1
Pages
34-39
Document Type
Article
EPub Date
2014/01/10
Status
Faculty; Northwell Researcher
Facility
School of Medicine; Northwell Health
Primary Department
Nephrology
PMID
DOI
10.1038/ki.2013.528